Next Phase Newsletter

The strategic fund of a biopharmaceutical company based in Western Europe is aligned with the parent company’s strategy, focusing on technology investments related to oncology and infectious diseases. The firm has $150M under management and invests in the range of $1M – $10M per company. The Fund typically makes a first investment at Series A and currently aims to make 1-3 new equity investments a year.

The firm is mainly seeking digital health and healthcare IT investment opportunities at the pre-commercial or commercial stage that will either improve drug development or that will impact the patient journey (e.g., patient monitoring, digital therapeutics, clinical decision support systems) relating to oncology and infectious diseases.

The firm is very active and supportive of its portfolio companies. The Fund typically takes a board seat, and at times also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm headquartered in China invests in Chinese companies, or companies outside of China looking to enter the Chinese market. The firm invests solely in the life sciences, with most (~70%) of their investments in therapeutics companies, and the rest in medical device companies. For most of their investments, the firm participates in the first institutional round, investing between $7-15M, or the equivalent in RMB. The firm invests early, and in some cases acts as a venture builder as well as an investor.

The firm is primarily interested in therapeutics companies, with over half of their investments in this space. The firm is opportunistic in terms of indication, but is especially interested in new modalities within therapeutics, such as cell and gene therapies, or therapeutics in areas with high barriers to entry. For medical devices, the firm prefers technologies relating to surgical robotics and minimally invasive procedures.

The firm is an active investor, almost always taking a board seat and using their network to help the companies advance. This can come in the form of helping them round out their management team, or, if the company is looking to enter the China market, through joint ventures or help navigating the regulatory requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed-stage venture fund is focusing on the frontiers of the intersection of science and technology. The firm looks for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. For all investments, the firm prefers that there is a deep data science or computational element to the technology being commercialized. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. Ideally, these technologies are also leveraging computation to accomplish their ends. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance.

The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials.

While a management team must be in place, the firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a large conglomerate with several global offices has two sites in the US is actively seeking new investment opportunities. In 2021, the firm raised a dedicated life science fund to invest in therapeutic and bioprocessing companies with flexibility of entering at different stages of development. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities globally.

The firm will make new investments from both traditional funds and the new life science fund. The traditional funds invest in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The new life science fund is interested in therapeutics, particularly gene therapy, ADC technologies, RNA delivery platform technologies, and bioprocessing business that support these strategic areas of interest.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A premier investment bank affiliated with a major conglomerate has an investment arm that invests across public, private, and mezzanine asset classes across various industries, including life sciences and healthcare. The firm is stage agnostic, but has invested in pre-Series A and Series A rounds and has an increased interest in early-stage technologies. Investments can be made out of the firms’ proprietary capital or through special purpose vehicles (SPVs). The firm is interested in global opportunities.

The firm is interested in all healthcare verticals: therapeutics, life science tools and diagnostics, medical devices, and digital health.  Within therapeutics, the firm is open to all types of modalities, indications, and therapeutic classes. The firm is stage agnostic and has invested in all rounds from pre-A to crossover rounds.

The firm has no specific company or management requirements. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Western Europe invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.

In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the firm invests in companies that are revenue positive. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.

In therapeutic opportunities, The firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, The firm seeks to co-invest in rounds led by top-tier Venture Capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.